Sri Kota Puts the Nursing Lens On Recent Data With Sacituzumab Govitecan in TROPiCs-02
October 26th 2022Sri Kota, MSN, BA, RN, OCN, unpacks data from the phase 3 TROPiCS-02 trial and highlights what nurses should know about sacituzumab govitecan for patients with advanced hormone receptor–positive, HER2-negative breast cancer.
FDA Approves Durvalumab in Combination with Tremelimumab for Unresectable HCC
October 24th 2022The combination of durvalumab and tremelimumab has been approved for patients with unresectable hepatocellular carcinoma. The combination comes with warnings for immune-related adverse events and infusion reactions.
Sacituzumab Govitecan Receives Priority Review Status for HR+/HER2- Metastatic Breast Cancer
October 14th 2022Following promising efficacy data from the phase 3 TROPiCS-02 trial, the FDA has granted sacituzumab govitecan priority review status on the indication of HR+/HER2 metastatic breast cancer.
States With Medicaid Expansion Experience Improved Cancer Care Delivery
October 13th 2022At the 2022 ASCO Quality Care Symposium, researchers discussed how Medicaid expansion was tied to earlier diagnoses, more accessible palliative care, and decreased mortality rates for patients with cancer.
Dose Reductions Help Patients with Breast Cancer Stay on Abemaciclib Longer
October 11th 2022At the 2022 ASCO Quality Care Symposium, an adverse event analysis showed that abemaciclib has a manageable safety profile and that dose reductions may be a key aspect of appropriate symptom management.